[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.236.145.124. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 304
Citations 0
Editorial
May 2017

Heart Failure With Reduced Ejection Fraction in Human Immunodeficiency Virus Infection: The More Things Stay the Same

Author Affiliations
  • 1Duke Clinical Research Institute, Duke University, Durham, North Carolina
JAMA Cardiol. 2017;2(5):476-477. doi:10.1001/jamacardio.2017.0282

Heart failure is a recognized complication of human immunodeficiency virus (HIV) infection dating back to the first case report in 1986.1 Over the subsequent years, the prevailing view of heart failure (HF) in HIV infection has evolved significantly. It is commonly suggested and at least 1 review has shown that in the era of antiretroviral therapy (ART), systolic dysfunction has become less common than diastolic dysfunction in people living with HIV (PLWH).2 Heart failure with reduced ejection fraction (HFrEF) and HIV-associated cardiomyopathies are thought to be pertinent mostly to PLWH in the era before widespread access to ART or in developing countries.3 In this issue of JAMA Cardiology, robust data from a large epidemiological study provide key insights into the contemporary epidemiology of HF in PLWH.4

×